4CPS-101 Biologic agents in rheumatological diseases: impact of ‘treat to target’ in clinical practice

Background and importanceThe aim of rheumatological diseases (RD) treatment should be clinical remission (CR) or alternatively a state of low level of clinical activity. The treatment of RD with a ‘treat to target’ (T2T) strategy consists of measuring and recording disease activity at each visit. If the patient has not reached the desired goal, therapeutic adjustments should be made to achieve it, and if the patient reaches CR then optimisation strategies (OS) can be performed: spacing or dose reductions.Aim and objectivesMeasure the impact of T2T strategy in terms of effectiveness, safety and economic saving in rheumatological patients (RP) treated with biological agents (BA).Material and methodsA retrospective analysis was conducted in RP treated with BA with at least 3 months of treatment since April 2009 to August 2021. We registered: sex, age, type of RD, responder patients: DAS-28